Is Indo US Bio-Tech overvalued or undervalued?

As of 17 November 2025, the valuation grade for Indo US Bio-Tech has moved from attractive to very attractive, indicating a significant positive shift in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 14.72, an EV to EBITDA ratio of 13.32, and a PEG ratio of 0.34, all of which suggest that the company is trading at a lower valuation relative to its growth prospects.
In comparison to its peers, Indo US Bio-Tech stands out with a much lower PE ratio than Jain Irrigation at 58.32 and Krishival Foods at 75.54, which are classified as very expensive. Additionally, the company's ROCE of 19.14% and ROE of 21.50% further highlight its operational efficiency and profitability relative to its valuation. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date decline of 60.67% compared to the Sensex's 8.72% gain, the underlying fundamentals suggest that Indo US Bio-Tech presents an attractive investment opportunity at its current price of 123.90.